Fremanezumab Treatment of Migraine in Women With Menstrual Migraine Ages 18-45

PHASE4RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 1, 2024

Primary Completion Date

January 1, 2026

Study Completion Date

July 30, 2026

Conditions

MigraineMenstrual MigraineMenstrually Related Migraine

Interventions

DRUG

Fremanezumab

The intervention will be active medication.

OTHER

Placebo

The intervention will be placebo injection.

Trial Locations (1)

RECRUITING

Brigham and Women's Health Care Center, Chestnut Hill

All Listed Sponsors

collaborator

Teva Pharmaceuticals USA

INDUSTRY

lead

Brigham and Women's Hospital

OTHER

NCT06173661 - Fremanezumab Treatment of Migraine in Women With Menstrual Migraine Ages 18-45 | Biotech Hunter | Biotech Hunter